Clinical trials: Head and Neck Cancers- Squamous Cell
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Squamous Cell
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in…
- Trial name
- NCT04892173
- Testing
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Where
- 196 sites in United States, Austria and 25 more
- Volunteers
- 500 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Head and Neck Cancer Squamous Cell
Reirradiation and Erbitux in the HNSCC
The purpose of this study is to investigate in patients with cancer of the throat and recurrent inoperable a different modality treatment consisting of radiation continuously for 5 weeks and half associated with a drug directed…
- Trial name
- NCT01237483
- Testing
- Erbitux
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
For esophageal cancer that can not be removed by surgery, the choice of treatment is a combination of chemotherapy and radiotherapy. We call this combination- (or concurrent) chemoradiotherapy.
- Trial name
- PANORAMIC (NCT01262183)
- Testing
- CRT + Panitumumab, Concurrent chemoradiation therapy without panitumumab
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Radboud University Medical Center
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to…
- Conditions
- Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm
- Trial name
- NCT03590054
- Testing
- Abexinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rahul Aggarwal
Head and Neck Squamous Cell Carcinoma
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
- Trial name
- NCT05272696
- Testing
- Nab-paclitaxel, cisplatin and Pembrolizumab combination, surgery, Adjuvant Chemoradiotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Guangdong Provincial People's Hospital
Neoplasms, Head and Neck
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
- Trial name
- JADE (NCT06256588)
- Testing
- Dostarlimab
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 864 people
- Sponsor
- GlaxoSmithKline
Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Reactivating NK Cells in Treating Refractory Head and Neck Cancer
This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.
- Trial name
- NKEXPHNC (NCT02507154)
- Testing
- Cetuximab + NK cells
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Carcinoma, Squamous Cell, Oesophageal Cancer
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the…
- Trial name
- TAPESTRY (NCT04481256)
- Testing
- External beam radiotherapy, Bintrafusp alfa, Paclitaxel
- Where
- Netherlands
- Volunteers
- 49 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects
Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions
This investigation was carried out to analyze and compare the salivary paxillin levels between oral premalignant and malignant lesions (OPMLs), OSCC and the healthy controls in order to assess its potential role as a biomarker of…
- Trial name
- NCT06154551
- Testing
- Paxillin biomarker
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cairo University
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002702
- Testing
- aldesleukin, adjuvant therapy, conventional surgery
- Where
- 7 sites in Italy
- Volunteers
- 260 people
- Sponsor
- European Institute of Oncology
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
3D Specimen Maps for RT Planning
The primary objective of this study is to measure the impact of patient-specific 3D specimen maps on adjuvant radiation treatment volumes and doses to critical organs.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Radiation Therapy
- Trial name
- NCT05743569
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt University Medical Center
Squamous Cell Carcinoma of the Oral Cavity
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan.
- Trial name
- NCT04387682
- Testing
- β-glucan
- Where
- Taiwan
- Volunteers
- 130 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Neoplasms
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.
- Trial name
- NCT03020823
- Testing
- SCB01A
- Where
- 4 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Borderline Resectable Carcinoma, Unresectable Cancer
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality.
- Conditions
- Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
- Trial name
- ILDR-03 (NCT07339488)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Chuangzhen Chen
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for…
- Trial name
- NCT07844551
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab, Cisplatin
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Head and Neck Neoplasms
Prospective Evaluation of ENDOSWIR Device Versus Pathology for Squamous Cell Carcinoma of Upper Aerodigestive Tract (ENDOSWIR-VADS)
A new medical optical device named ENDOSWIR is tested to determine its ability to determine if tissues are cancer or normal tissue on ex-vivo condition for specimen of ENT squamous cell cancers.
- Trial name
- ENDOSWIR-VADS (NCT05318872)
- Testing
- ENDOSWIR
- Volunteers
- 10 people
- Sponsor
- University Hospital, Grenoble
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Oral Cavity Squamous Cell Carcinoma
Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience
Sentinel node biopsy is a suitable alternative to END and is recommended in standard guidelines. Investigators have been doing SNB in their department to standardize the process for the last two years.
- Trial name
- NCT05950737
- Testing
- Sentinel node biopsy
- Where
- India
- Volunteers
- 115 people
- Sponsor
- Tata Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.